Online inquiry

IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4734MR)

This product GTTS-WQ4734MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL21 gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001207006.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 59067
UniProt ID Q9HBE4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ4734MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2337MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ALXN6000
GTTS-WQ12826MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMS721
GTTS-WQ12832MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ONC-005
GTTS-WQ3875MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-100
GTTS-WQ14949MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SHR-1210
GTTS-WQ1707MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ6549MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA D2E7
GTTS-WQ5178MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CAT-354
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW